Stock Taper
SCREENER COMPARE ANY 2 STOCKS
BTAI
BIOXCEL THERAPEUTICS, INC.
NASDAQ
$0.18
▼ DOWN 74.76% (-0.54)

KEY STATISTICS

Market Cap$5.60 M
52w High$4.29
52w Low$0.16
Dividend Yield—
Frequency—
P/E-0.03
Volume57.53M
Shares Out.30.88M

COMPANY

LEADERSHIP

Vimal D. Mehta
CHIEF EXECUTIVE
Vimal D. Mehta

COMPENSATION 2026

Salary$1,001,570
Stock Awards$0
Incentive Plan Pay$0
All Other Comp.$16,425
Total$1,119,245

ABOUT

SECTOR
Healthcare
WENT PUBLIC
March 8, 2018
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
29

PRICE TARGET

Target High$25.00
Target Low$1.00
Target Median$10.00
Target Consensus$12.00

UPCOMING EARNINGS

DateNov 11, 2026
DayWednesday
Rev. Est.$191.39K
NOV
11
WED

SPLIT RECORD

DATETYPERATIO
2025-02-10Reverse1:16

PRICE

$0.18 ▼ DOWN 74.76% (−$0.54)
OVERLAYS
$0.16$0.18$0.20$0.229:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM0.18

About BioXcel Therapeutics, Inc.

https://www.bioxceltherapeutics.com ↗

BioXcel Therapeutics, Inc. is a biopharma company using AI and big data to develop innovative medicines in neuroscience and immuno-oncology, with products like IGALMI for agitation and ongoing trials for dementia, depression, and cancer.

INDUSTRY

Biotechnology

A PRODUCT BIOXCEL THERAPEUTICS, INC. IS KNOWN FOR

IGALMI® (dexmedetomidine) sublingual film
IGALMI® (dexmedetomidine) sublingual film

IGALMI is an FDA-approved sublingual dexmedetomidine film for acute agitation in adults with schizophrenia or bipolar disorder, serving as the company's flagship product and focus in neuroscience innovation.

COMPETITORS

COMPETITOR
ALKS COMPARE
AXSM COMPARE
BMY COMPARE
VNDA COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
13
LISTED HERE
2
RANKED BY POSITION SIZE
VTI
0.00% · 679.6K
IWC
0.00% · 90.4K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
18.93%
HOLDERS
56
TOP 12 OF 56 · RANKED BY POSITION SIZE
Millennium Management LLC
1.9M sh · $2.6M
Armistice Capital, LLC
1.9M sh · $2.56M
Blackrock Inc.
440.7K sh · $564.08K
Vanguard Group Inc
292.8K sh · $468.4K
Oaktree Capital Management LP
241.2K sh · $323.19K
Geode Capital Management, LLC
230.2K sh · $308.73K
Fmr LLC
198.6K sh · $508.42K
Jones Financial Companies Lllp
137.7K sh · $220.3K
Jane Street Group, LLC
127.5K sh · $204K
Gsa Capital Partners Llp
120.1K sh · $192K
Xtx Topco Ltd
113.4K sh · $290.21K
Man Group Plc
96.5K sh · $129.27K

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity5
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score2

INSIDER TRADES

★
DIRECTOR
Atkins Susan E.
Purchase · 17.0K shares
2026-08-12
★
DIRECTOR:
Atkins Susan E.
— · —
2026-08-12
★
OFFICER: SEE REMARKS
Rodriguez Javier
Sale · 35 shares
2026-06-15
★
DIRECTOR, OFFICER: CEO AND PRESIDENT
Mehta Vimal
Purchase · 219 shares
2026-06-15

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 1
NEUTRAL 1
2 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. BUY Mizuho NEUTRAL

SECTORS PEERS

PEERPRICE
PYPD$5.07COMPARE
ANVS$1.72COMPARE
CELU$1.58COMPARE
VERU$2.63COMPARE
EVAX$3.01COMPARE
RVPH$0.52COMPARE
BCAB$1.74COMPARE